Leila-Sophie Otten

9PUBLICATIONS
24CO-AUTHORS
PharmacogenomicsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular medicineApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Sep 06, 2026
Translational modelling challenges receptor‑occupancy‑based dosing of PD‑1 inhibitors like pembrolizumab.

|Jul 24, 2025
Early pembrolizumab clearance as prognostic biomarker for non-response in patients with advanced non-small cell lung cancer.

Fenna de Vries, Leila-Sophie Otten, Berber Piet

|May 27, 2025
Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment.

Nikki de Rouw, Leila-Sophie Otten, Mart P Kicken

|Jan 28, 2025
Very Early Health Technology Assessment for Potential Predictive Biomarkers in the Treatment of Advanced Non-Small Cell Lung Cancer.

Leila-Sophie Otten, Alessandra I G Buma, Berber Piet

|Jun 11, 2024
Proactive monitoring of drug-drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer.

Judith L Gulikers, Leila-Sophie Otten, Lizza E L Hendriks

|Oct 19, 2023
Prognostic Value of Nivolumab Clearance in Non-Small Cell Lung Cancer Patients for Survival Early in Treatment.

Leila S Otten, Berber Piet, Demy van den Haak

Pageof 2

Frequent Collaborators

3 joint publications

Berber Piet

3 joint publications

Rob Ter Heine

2 joint publications

Lizza E L Hendriks

1 joint publications

Verena C Mulder